A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution

• Status: Completed
• Trial end date: 2000-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and tolerability of INS365 Ophthalmic Solution when applied topically as eyedrops in patients with mild to moderate dry eye disease.

• Phase: Phase 2

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Best corrected visual acuity 20/40 in each eye

• 2 out 5 specified symptoms

• Corneal fluorescein staining score greater than or equal to 3 out of 15

Exclusion Criteria:

• Unable to stop concomitant medications

• Have had intraocular surgery in previous 90 days

• Have excluded systemic or ocular disease

• Wear contact lenses and are not willing to remove them

• Have intraocular pressure greater than 22 mg Hg